Sokar

Treatment of urge incontinence in adults with overactive bladder

QUALITATIVE AND QUANTITATIVE COMPOSITION

Each prolonged-release tablet contains 8 mg fesoterodine fumarate corresponding to 6.2 mg of fesoterodine.

PHARMACEUTICAL FORM

Prolonged-release tablet.

THERAPEUTIC INDICATION

Sokar is indicated in adults for treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur with overactive bladder syndrome.

DISPENSING AND REIMBURSEMENT

Medicinal product is subjected to medical prescription. The medicinal product is covered by public health insurance.

Mandatory information

Summary of product characteristic Package leaflet

Back